Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers

Table 1

Summary of the methodological characteristics of the included studies.

Registry	Study name	Study duration	Year of entry	Study country	Number of patients included	Biologic-; naive (%)
Biologic-naive
DREAM	Flendrie et al. 2003 [1]	Maximum follow-up time for ADA, INF, and ETN was 69 months, 35 months, and 30 months, respectively.	ADA was started between April 1997 and September 2000, INF was started since January 2000, and ETN was started since February 2000	The Netherlands	230	100
SCQM	Genta et al. 2006 [2]	38 month-follow-up	Before February 2003	Switzerland	66	100
DANBIO	Hetland et al. 2010 [3]	The median (IQR) follow-up times were as follows: for ADA, 20 months (IQR: 7 months–39 months); for ETN, 21 months (IQR: 9 months–42 months); and for INF, 16 months (IQR: 5 months–36 months)	October 2000 to 31 December 2007	Denmark	2326	100
BSRBR	Hyrich et al. 2007 [4]	The mean length of follow-up per patient was 15 months (maximum 61 months)	Patients who completed minimum 6 months of follow-up by the end of April 2005	UK	6739	100
GISEA	Iannone et al. 2011 [5]	48 months	2003-2004	Italy	853	100
DREAM	Kievit et al. 2007 [6]	Mean follow-up duration was 20 months for INF cohort and 13 months for ETN and ADA cohorts	April 2003 to December 2005	The Netherlands	546	100
DREAM	Kievit et al. 2008 [7]	12 months	February 2003 to August 2007	The Netherlands	707	100
LOHREN	Marchesoni et al. 2009 [8]	36 months	1999	Italy	1064	100
BSRBR	Hyrich et al. 2006 [9]	6 months (minimum follow-up duration)	Only those patients who had reached six month follow-up prior to 1 October 2004 were included	UK	3223	100
BSRBR	Hyrich et al. 2006b [10]	6 months	Not reported	UK	2711	100
DANBIO	Østergaard et al. 2007 [11]	Not reported	Before October 2002	Denmark	417	100
Mixed (biologic pretreated and biologic-naive)
SCQM	Finckh et al. 2006 [12]	The median follow-up time for ADA, INF, and ETN was 10.7 months (IQR: 5.8 months–12.3 months), 18.8 months (IQR: 11.5 months–28.3 months), and 23.7 months (IQR: 12.6 months–35.8 months), respectively.	Between January 1998 and September 2004	Switzerland	1198	83
SCQM	Pan et al. 2009 [13]	Not reported	January 1997 to December 2006	Switzerland	2364	77
RABBIT	Strangfeld et al. 2009 [14]	36 months	1 May 2001 to 31 December 2006	Germany	1769	81
RABBIT	Zink et al. 2006 [15]	12 months	Between May 1 2001 and December 31 2004	Germany	1458	78.3
RABBIT	Zink et al. 2005 [16]	Not reported	Patients enrolled between May 2001 and September 2003, were included and followed up to March 2004.	Germany	1523	87.9

ARTIS: Antirheumatic Therapies in Sweden; ATTRA: Anti-TNF treatment of rheumatoid arthritis; BIOBADASER: Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología; BSRBR: British Society for Rheumatology Biologics Register; DANBIO: Danish Biologic Registry; DAS: disease activity score; DMARDs: disease-modifying antirheumatic drugs; DREAM: Dutch Rheumatoid Arthritis Monitoring; EMECAR: Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide; GISEA: Italian Group for the Study of Early Arthritis; LOHREN: Lombardy Rheumatology Network; NOR-DMARD: Norwegian Disease-modifying antirheumatic Drugs; RABBIT: rheumatoid arthritis observation of biologic therapy; RA: rheumatoid arthritis; RATIO: French Research Axed on Tolerance of Biotherapies; ROB-FIN: Register of Biological Treatment in Finland; SCQM: Swiss Clinical Quality Management in Rheumatic Diseases; SSATG: Southern Sweden Antirheumatic Therapy Group; STURE: Stockholm Tumour Necrosis Factor-𝛼 Follow-up Registry; TNF: tumour necrosis factor; UK: United Kingdom.